Background
==========

Lemierre's syndrome, also known as the "forgotten disease" is a rare entity typically characterized by thrombosis of the internal jugular vein and its tributaries. This very often follows an oropharyngeal infection \[[@b1-amjcaserep-21-e916575]\]. First described by the Frenchman Andre Lemierre in 1936, it is considered to be rare with a reported incidence of about 0.8 million cases per year \[[@b1-amjcaserep-21-e916575]\]. It usually occurs in otherwise healthy individuals in their second decade, with a disproportionately high male preponderance \[[@b2-amjcaserep-21-e916575]\]. Complications can be life threatening in cases without early intervention. These include overwhelming bacteremia, malignant cellulitis, metastatic abscesses, and septic emboli (with special predilection for the lungs) \[[@b2-amjcaserep-21-e916575]\]. Although, in 90% of reported Lemierre's syndromes the causative agent is the anaerobic oral commensal *Fusobacterium necrophorum* \[[@b3-amjcaserep-21-e916575]\], other *Fusobacterium* species, some anaerobes, *Streptococci,* and *Staphylococcus aureus* (both methicillin-sensitive *Staphylococcus aureus* \[MSSA\] and methicillin-resistant *Staphylococcus aureus* \[MRSA\]) have also been reported \[[@b4-amjcaserep-21-e916575]\]. Diagnostic criteria for classical Lemierre's syndrome include positive blood cultures, and radiological evidence of internal jugular vein thrombophlebitis \[[@b5-amjcaserep-21-e916575]\]. We report a case of a young male patient with history of recent herpes zoster infection who presented with orbital cellulitis secondary to malignant *Staphylococcus aureus* facial infection. This subsequently caused superior ophthalmic vein thrombosis as part of his other clinical sequelae. He was treated early with intravenous antibiotics, antiviral agents, and an early strategy of anticoagulation to prevent debilitating complications.

Case Report
===========

A 31-year-old healthy male presented to the emergency department with a week's history of increasing redness and left-sided nose swelling that gradually involved his left eye. A few days prior to the onset of his current symptoms, he had developed a painful blistering rash on his left anterior nares, which was managed as herpes zoster exanthema. On examination, he looked in pain, there was left upper eyelid swelling with ptosis. He additionally had erythematous crusting with vesicular lesions on the lateral aspect of nose, as well as mild conjunctival injection. There were no cranial nerve deficits, and the rest of his neurological, cardio-respiratory, and abdominal examinations were unremarkable. Herpetic ocular involvement was ruled out by fluorescein examination. He was afebrile, with a saturation of 100% on room air, pulse rate of 88 beats per minute, and blood pressure of 136/78 mm Hg. Electrocardiogram (ECG) showed normal sinus rhythm. Initial biochemistry was significant for leukocytosis with a white blood cell count of 15.7×10^3^/uL, and an absolute neutrophil count of 12×10^3^/uL. C-reactive protein (CRP) was elevated at 269.1 mg/L. Other electrolytes including kidney, liver, and coagulation profiles were within normal limits. Chest x-ray showed clear lung fields. Computed tomography (CT) of both orbits and facial bones ([Figure 1](#f1-amjcaserep-21-e916575){ref-type="fig"}) were suggestive of cellulitis in left periorbital region extending to the left nasal bone, the maxilla, left side of his face, as well as partial thrombosis of left facial vein. He was commenced empirically on intravenous (IV) meropenem, and acyclovir. On the second day of admission, he started to spike a high-grade fever of 38.4°C accompanied by tachycardia (124 beats per minute). Initial blood and skin pustule aspirate cultures grew methicillin sensitive *Staphylococcus aureus*. Echocardiogram ruled out valvular vegetations or heart valve thrombosis. Subsequent magnetic resonance imaging (MRI)/magnetic resonance venography (MRV) of his orbits with contrast ([Figures 2](#f2-amjcaserep-21-e916575){ref-type="fig"}, [3](#f3-amjcaserep-21-e916575){ref-type="fig"}) confirmed left-sided periorbital and pre-septal soft tissue swelling, retro-orbital fat stranding, and left superior ophthalmic vein thrombosis. Over the next couple of days his vital parameters returned to baseline. On day 5, he was switched to IV cloxacillin, to complete a total antibiotic course of 4 weeks duration. Anti-coagulation was also initiated to reduce the risk of recurrent venous thromboembolism (VTE) with initial low molecular weight heparin, which was ultimately transitioned to warfarin for 3 months. [Table 1](#t1-amjcaserep-21-e916575){ref-type="table"} gives the clinical course of his hospital stay

Discussion
==========

Anaerobic post anginal septicemia was Andre Lemierre's first definition of this disease in 1936 \[[@b15-amjcaserep-21-e916575]\] after publishing a series of 20 cases in which anaerobic sepsis was preceded by a throat infection. We currently recognize the disease as an oropharyngeal infection followed by septicemia, thrombophlebitis at the primary site of infection, and distant metastatic abscesses due to migrating septic thrombotic plaques \[[@b16-amjcaserep-21-e916575]\]. It is assumed that an increase in factor VIII may be a key contributing factor in thrombosis of these patients. In the pre-antibiotic era, Lemierre's syndrome had a reported mortality rate of approximately 100% \[[@b1-amjcaserep-21-e916575]\]. While the basic phenotype of the disease has remained largely the same, there has been considerable reduction in both morbidity and mortality associated with it.

In this report we have discussed an atypical presentation and a rare clinical course of Lemierre's syndrome both in the microbiologic agent involved (*Staphylococcus aureus)* as well as the disposition of venous thrombosis (superior ophthalmic vein thrombosis). The latter probably due to super-imposed infection of nasal herpetic lesions. The clinical course of our patient including morbidity parameters such as microbiological response, and length of hospital stay fits within the ballpark reported from recent reports. Our patient's initial complaint of facial swelling and orbital pain is very interesting, as orbital pain as the key index presentation is variable from most recent reports \[[@b17-amjcaserep-21-e916575]\]. To compare the clinical course of our patient in the context of other reports, we reviewed a series of current literature and recent presentations (especially atypical blood culture isolates, as well as territory of venous system thrombosis involved). This is given in [Table 2](#t2-amjcaserep-21-e916575){ref-type="table"}. In a report by Karkos et al., for example, analyzing case reports from 1940 to 2007, only 1% of the cases had orbital pain as an initial presentation \[[@b17-amjcaserep-21-e916575]\]. The territory of associated venous thromboembolism in this report also showed a remarkably low involvement of venous systems other than the internal jugular vein. Out of 86 case reports reviewed for example, only 1 was complicated by superior ophthalmic vein thrombosis. The novelty of our patient presentation with superior ophthalmic vein thrombosis adds to increasing incidence of venous systems involvement outside of the internal jugular venous system. While the exact explanation for this remains debatable, the preponderance of the primary focus of infection/inflammation may perhaps offer an insight into the mechanism thromboembolism in these cohorts of patients. There was no reported case caused by *Staphylococcus aureus* prior to this series \[[@b17-amjcaserep-21-e916575]\]. To the best of our knowledge, there has not been a reported case of super-imposed herpetic lesions causing Lemierre's syndrome.

The exact role of other agents such as *Staphylococcus aureus* has evolved over the years. Only recently has *Staphylococcus aureus* been identified as a plausible cause of Lemierre's syndrome with most isolates growing either methicillin resistant *Staphylococcus aureus* or Panton-Valentine Leucocidin (PVL) toxin producers \[[@b18-amjcaserep-21-e916575]\]. It is an opportunistic organism that colonizes skin and soft tissue. The mechanism of bypassing the immune response following staphylococcal infection, has been suggested to be primarily neutrophilic and phagocytic. It accomplishes resisting destruction after being ingested by a phagocyte, inhibit leukocytic chemotaxis, evade hosts antibodies, and utilizing its polysaccharide capsule conceal itself from the hosts detection system \[[@b19-amjcaserep-21-e916575]\] The PVL toxin is particularly virulent and is considered to be one of the most severe toxins produced, with a robust ability to lyse human white blood cells \[[@b19-amjcaserep-21-e916575]\].

Most of the initial and by far a significant proportion of reports of Lemierre's syndrome were associated with *Fusobacterium necrophorum* as the causative organism in two-thirds of the cases. Other organisms are considered atypical and *Staphylococcus aureus* is still considered to be a rare cause \[[@b20-amjcaserep-21-e916575]\]. The skin has been suggested to be the commonest site for primary staphylococcal infection in this cohort of patients \[[@b21-amjcaserep-21-e916575]\]. In one study, 40% of patients from an outpatient setting had *Staphylococcus aureus* colonization in their nasal carriage with the risk of potential overt bacteremia and its attendant complications \[[@b22-amjcaserep-21-e916575]\]. In a presentation similar to ours, Chanin et al. reported an immuno-competent individual that eventually had bacteremia but with a more adverse clinical course \[[@b20-amjcaserep-21-e916575]\]. This presumably was due to the patient's late presentation, and a methicillin-resistant *Staphylococcus aureus* (MRSA) isolate. Similarly, Kadhiravan et al. \[[@b23-amjcaserep-21-e916575]\]. reported a young healthy individual admitted with orbital cellulitis (similar to our case), however, as was the case with previously described reports (including Chanin et al. \[[@b20-amjcaserep-21-e916575]\]), this patient's clinical course was rather complicated. Probably explanation suggested for this stormy clinical course includes septic embolism to her lungs, and bacteremia consistent with community acquired methicillin resistant *Staphylococcus aureus* (MRSA). Despite its previously reported rarity, there have been increasing reports of orbital cellulitis as the index presentation in these cohorts of patients \[[@b23-amjcaserep-21-e916575]\]. Kadhiravan et al. for example reported a case of a patient who presented with an incident painful eye swelling that was subsequently found confirmed to have orbital cellulitis on further imaging studies \[[@b23-amjcaserep-21-e916575]\]. In comparison, Shivashankar et al. reported on a similar case whose initial periorbital swelling was accompanied by multiple cranial nerve deficits due to migrating septic thrombophlebitis to the cavernous sinus with attendant multiple brain infarction \[[@b11-amjcaserep-21-e916575]\].

The exact location of venous thromboembolism in these cohorts of patients has also attracted considerable interest. Although the initial site of the first report \[[@b1-amjcaserep-21-e916575]\] appears to be the internal jugular vein, further propagation has varied in subsequent reports since. The most common area of thrombus propagation in the venous territory is superiorly from the internal jugular veins to sigmoid and cavernous sinuses and inferiorly to the subclavian vein \[[@b24-amjcaserep-21-e916575]\] Propagation to the superior branch of ophthalmic vein has not yet been reported in current literature to the best of our knowledge.

How initial or associated viral exanthema such herpes zoster contributes to or predispose vulnerable patients to Lemierre's syndrome remains uncertain. Among the few that have reported on this includes Etienne et al. \[[@b14-amjcaserep-21-e916575]\] whose patient presentation, clinical course, patient demography (young, immune-competent), and microbiological isolate (*Staphylococcus aureus)* bore resemblance to our case. The typical duration of antimicrobial therapy is 4 to 6 weeks, while the need and the exact strategy for anti-coagulation still remains a matter for ongoing debate (with administration in only 20% to 30% of documented case reports). In our patient, we continued IV antibiotics for a duration of 4 weeks and anticoagulation from low molecular weight heparin to warfarin for 3 months.

What has, however, remained unresolved is both the apparent and real increase in incidence of this syndrome. A plausible explanation might be due to increasing vigilance from improving awareness about this entity. Other factors may include, increasing reluctance for empirical antibiotic therapy in patient's presenting with evolving staphylococcal skin infections due to the ever-increasing demands of antibiotic stewardship. Other factors include improved diagnostic capacity of recent generation CT and MRI scanners at resolving sub-clinical incidental clots that may have been unapparent on earlier generation scanners.

Limitations
===========

One of the major limitations of our report was the inability to obtain the exact strain of *Staphylococcus aureus.* We suspect that the phenotype, and clinical course of our patient suggests that the *Staphylococcus aureus* isolated was probably a PVL toxin producing variety. Additionally, we were unable to ascertain the exact role of concomitant herpes zoster infection our patient had prior to hospital presentation to his ultimate definitive diagnosis of Lemierre's syndrome.

Conclusions
===========

*Staphylococcus aureus* skin infection is a very rare cause of Lemierre's syndrome, and superior ophthalmic vein thrombosis has not yet been reported in literature. It is important to acknowledge the potential risk of superadded infection of herpes zoster. Early recognition of Lemierre's syndrome contributes significantly in reducing its morbidity and mortality.

**Lessons and future perspectives**

As clinicians we must always consider both classical and modified presentations of this syndrome in the setting of facial cellulitis with a bacterial isolate, due to the additional possibilities of morbidity that may need treatment such as associated venous thromboembolisms.
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###### 

An overview of the clinical course of his hospital stay with kinetics of key biochemical parameters as a function of antimicrobial therapy.

  **Antibiotic day**   **Temperature °C (oral)**   **WBC (10.1×10^3^/uL)**   **CRP (mg/L)**
  -------------------- --------------------------- ------------------------- ----------------
  1                    36.9                        15.7                      269
  2                    38.4                        --                        --
  4                    37                          --                        62
  6                    36.9                        10.1                      --
  15                   36.8                        8                         --
  28                   37                          7.2                       --

WBC -- white blood cell; CRP -- C-reactive protein.

###### 

An overview of blood culture isolates as a function of differential veno-thrombotic territory.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study (reference)**                                   **Year**   **Gender**   **Territory of venous system thrombosis**                  **Blood culture isolate**
  ------------------------------------------------------- ---------- ------------ ---------------------------------------------------------- ------------------------------------------------------------------
  Takiguchi et al. \[[@b6-amjcaserep-21-e916575]\]        2017       Female       Left external jugular                                      Group C Streptococcus

  Kadhiravan et al. \[[@b7-amjcaserep-21-e916575]\]       2008       Female       Right internal jugular extending to superior vena cava     Community acquired methicillin resistant *Staphylococcus aureus*

  Boga et al. \[[@b8-amjcaserep-21-e916575]\]             2007       Male         Right internal jugular Splenic vein                        *Staphylococcus aureus*

  Singaporewalla et al. \[[@b9-amjcaserep-21-e916575]\]   2006       Male         Left internal jugular                                      *Klebsiella pneumonia*

  Stauffer et al. \[[@b10-amjcaserep-21-e916575]\]        2012       Female       Bilateral cavernous sinus and ophthalmic vein thromboses   Community acquired methicillin resistant *Staphylococcus aureus*

  Shivashankar \[[@b11-amjcaserep-21-e916575]\]           2008       Male         Cavernous sinus extending to left internal jugular         Panton-Valentine leucocidin-producing *Staphylococcus aureus*

  Tsai et al. \[[@b12-amjcaserep-21-e916575]\]            2014       Female       Left internal jugular vein extending to sigmoid sinus      *Klebsiella pneumonia*

  Krishna et al. \[[@b4-amjcaserep-21-e916575]\]          2012       Male         Left lateral sigmoid sinus\                                *Staphylococcus aureus*
                                                                                  Left internal jugular                                      

  Agawaral et al. \[[@b13-amjcaserep-21-e916575]\]        2013       Male         Right internal jugular extending to subclavian             Methicillin resistant *Staphylococcus aureus*

  Etienne et al. \[[@b14-amjcaserep-21-e916575]\]         2008       Female       Right internal and external jugular                        *Staphylococcus aureus*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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